ClinicalTrials.gg
Active, not recruitingNCT05633706Updated Sep 30, 2026

Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis

An observational study in Irritable Bowel Syndrome, Crohn Disease and Celiac Disease, sponsored by Nimble Science Ltd.. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Nimble Science Ltd. · Observational

How we know

Updated Sep 30, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
300
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Irritable Bowel Syndrome with a site in Canada — 8 open to participants now, 11 under way, 1 of them phase 3. Irritable Bowel Syndrome · Canada.

Started
2023
with 1 other
Observational
4 of 56
none open now
Primary completion
2027-06
later than 4 of 10 live
Registered
44th of 56
by date

Among the 56 studies in Irritable Bowel Syndrome with a site in Canada, this one is one of 2 that started in 2023, is one of 4 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 44th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

8 of the 56 studies in Irritable Bowel Syndrome with a site in Canada are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Irritable Bowel Syndrome with a site in Canada, or all of them as a file.
02

Study summary

The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means. The study will compare the microbial and metabolomics analysis from the sample collected with the capsule series, to same-participant symptom questionnaires and stool microbial analysis.

Read the detailed description

The investigators primary goal is to assess the correlation of gut symptoms from various disease states with the dysbiosis of the small intestinal microbiome and metabolites collected by the SIMBA capsule, and as identified and measured by metagenomic sequencing and/or metabolomics approaches. The process consists of ingestion and collection of up to 4 SIMBA capsules, on up to 2 separate occasions, along with collection of a stool sample at the same time. Participants will also fill out a series of questionnaires on medical history and lifestyle inputs (eg. diet, exercise, mental health) GI symptoms, anxiety, and depression. The investigators ultimate goal will be to develop a better understanding of how the small intestinal microbiome might play a role in symptom generation, to establish whether the SIMBA capsule can find a signature of dysbiosis which can be used as a biomarker for a number of functional gut disorders.

03

Conditions studied

  • Irritable Bowel Syndrome
  • Crohn Disease
  • Celiac Disease
  • Ulcerative Colitis
  • Functional Dyspepsia
  • Type 2 Diabetes
  • Healthy

Keywords

  • Microbiome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Up to 300 individuals, females or males will be enrolled in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 1. Aged between 18 and 80 years.
  2. No previous diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, Functional Dyspepsia, and T2D by participant self-report (Control group).
  3. Prior diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, or Functional Dyspepsia, and T2D by a relevant physician, nutritionist, naturopath, etc, and willingness to provide documentation to confirm this diagnosis or have a consultation with the PI. (Disease group).
  4. Ability to understand and provide .
  5. Ability and willingness to meet the required schedule, study interventions, and questionnaire requirements.
  6. No planned change in diet or medical interventions during the study duration.

Exclusion criteria

Exclusion Criteria

  1. Known disease which, in the investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, cancer diagnosis or treatment within the past year, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months prior to enrollment are acceptable). The main deciding factor would be a history of obstructive symptoms in the previous 3 months prior to entry.
  2. Use of any medications or having undergone procedures in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, laxatives, or GLP-1 analogues).

    1. Stimulant laxative use (includes bisacodyl/Dulcolax, senna/Senekot, cascara, or fibre supplments) is allowed if it is kept unchanged in the week prior to the SIMBA Capsule ingestion. Osmotic laxatives (polyethylene glycol (PEG; other trade names), milk of magnesia, lactulose), stool softeners (docusate; other trade names) or secretagogues (linaclotide/Constella, plecanatide/Trulance, tenapanor/Ibsrela should not be used within 7 days of taking the SIMBA capsules.
    2. Prokinetics use is allowed if kept unchanged in the week prior to the SIMBA Capsule ingestion (includes domperidone, metoclopramide, prucalopride). Inconsistent use of prokinetics will be evaluated by the PI.
    3. PPI or H2RA use. Must be able to discontinue PPI or H2RA medications 48hrs prior to SIMBA capsule ingestion, medication can be resumed 4 hours after ingestion.
  3. History of oropharyngeal dysphagia or other swallowing disorder with a risk of aspiration of the capsule.
  4. History of known structural gastrointestinal abnormalities such as strictures or fistulas leading to mechanical obstruction
  5. History of abdominal radiation treatment
  6. Females of childbearing age who are pregnant or lactating by self-report. (should an X-ray be required for confirmation of capsule passage, a urine pregnancy test will be administered beforehand).
  7. No antibiotics, or colon cleanses/bowel prep for 2 weeks.
  8. \< 2 bowel movements per week (Control Group only).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy

    Not belonging to the other cohorts as described below.

    Device: fluid biopsy capsule

  • Irritable Bowel Syndrome

    As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.

    Device: fluid biopsy capsule

  • Crohns Disease

    As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.

    Device: fluid biopsy capsule

  • Ulcerative Colitis

    As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.

    Device: fluid biopsy capsule

  • Celiac Disease

    As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.

    Device: fluid biopsy capsule

  • Functional Dyspepsia

    As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.

    Device: fluid biopsy capsule

  • Type 2 Diabetes

    As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.

    Device: fluid biopsy capsule

Interventions

  • Devicefluid biopsy capsule

    Collection of a fluid biopsy from the small intestine via ingestible capsule

06

What researchers measure

Primary outcomes

  1. Correlation of bacterial composition with gastrointestinal disease states as assessed by PLS-DA mapping.

    The bacterial composition of healthy control fluid biopsy is compared to the bacterial composition of participants with diagnosed gastrointestinal diseases, to aid in gastrointestinal disease biomarker discovery.

    Time frame: baseline, pre-procedure

Secondary outcomes

  1. Correlation of bacterial composition with dietary intake as assessed by PLS-DA mapping.

    Fluid biopsy bacterial composition correlated with self-reported long-term and short-term preferred variations in intake of dietary fiber and organic food.

    Time frame: baseline, pre-procedure

Other outcomes

  1. Usability of SIMBA capsule in various disease states as assessed by SIMBA-experience questionnaires.

    Participant feedback on SIMBA capsule usage experience will inform usability data.

    Time frame: immediately after the procedure

  2. Comparison of SIMBA fluid biopsy microbial composition to stool microbial composition as assessed by 16s rRNA metagenomic analysis.

    Time frame: baseline, pre-procedure

  3. Correlations of bacterial composition with anxiety (GAD-7) scores as assessed by PCoA mapping, alpha and beta diversity analysis.

    Time frame: baseline, pre-procedure

  4. Correlations of bacterial composition with depression (PHQ-8) scores as assessed by PCoA mapping, alpha and beta diversity analysis.

    Time frame: baseline, pre-procedure

  5. Correlations of bacterial composition with self-reported lifestyle behaviours as assessed by PCoA mapping, alpha and beta diversity analysis.

    Time frame: baseline, pre-procedure

  6. Number of participants with device-related adverse events as assessed by an independent Data Safety Monitoring Board.

    Time frame: through study completion, an average of 8 days

  7. Evaluate the usability of excreted SIMBA Capsule retrieval procedures as assessed by retrieval-experience questionnaire feedback.

    Time frame: immediately after the procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2023 (actual). Primary completion is estimated for Jun 2027, 53 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jun 2025 → Jun 2027 and completion Jun 2025 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Dec 1, 2022
StartActual
Jan 9, 2023
Primary completionEst.
Jun 2027was Jun 2025
CompletionEst.
Aug 2027was Jun 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Primary completion
Jun 6, 2025→Jun 2027
Sep 30, 2026
Study completion
Jun 6, 2025→Aug 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 6, 2025→Jun 2027
    Study completion Jun 6, 2025→Aug 2027
    + 6 other changes: index terms, verification date, oversight details, criteria formatting, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05633706
Lead sponsor
Nimble Science Ltd.
Collaborators
Mitacs, University of Calgary
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Jan 9, 2023
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Chris Andrews, MD
principal investigator · Nimble Science Ltd.
Matthew Woo, MD
principal investigator · Nimble Science Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion